Tags Posts tagged with "cbd"


0 1132

In Wisconsin, the subject of cannabis for medicinal purposes has been nearly untouched aside from a 2014 proposal that exempted patients with seizure afflictions and a doctor’s recommendation from arrest for possessing or using CBD oil. That proposal didn’t do much to help patients with seizures and nothing to help the many other patients who would benefit from medical cannabis. This year they are making another attempt at passing a CBD proposal that would legalize the use and possession cannabidiol for patients with a doctor’s prescription.

A similar proposal was introduced last year in the Assembly and passed, however, it never made it out of the Senate. This proposal was introduced in the Senate and was approved with a 31-1 vote, with the lone opponent Duey Stroebel, a Republican Senator. While this proposal will open up access to non-psychoactive CBD oil to patients beyond those with seizure disorders, many find that marijuana products with both THC and CBD are more beneficial for most disorders. This means that those this law will help are still greatly limited in comparison to patients in other medical cannabis states.

Sen. Chris Larson, D-Milwaukee, one of the bill’s co-sponsors stated, “If we had done this when the debate first started, it would have cut out four years of suffering for those kids, four years of anguish for those parents.” While it’s likely that this proposal will pass in the Assembly, considering a similar measure made it through last year, there are still too many flaws in the way it’s written. Not only do CBD-only laws limit the number of suffering patients that can legally benefit from medical cannabis, but many don’t create a legal way for patients to access this medicine once a doctor approves it for them in a prescription.

This proposal would not create in-state production or sale of CBD oil, so no matter how patients or caregivers go about it, they are still taking a legal risk just to obtain their medicine. However, while this bill does not go as far as it really needs to, it is at the very least a start. It will give many parents and patients the comfort of knowing at least part of the risk in using their preferred method of treatment has been taken away.

0 975

A proposal simplifying access to a therapy for seizures and other medical disorders has passed the state Senate, overcoming an obstacle that prevented the legislation in 2016. The measure offers a fix to Lydia’s Law, named after a 7-year-old Burlington girl who died in 2014. Lydia’s Law legalized cannabidiol (CBD oil) which is a cannabis extract shown to work for some children who suffer from seizures.

However, supporters say Lydia’s Law has not worked as intended because Wisconsin families have not been able to access the oil. Under the bill, a person can possess CBD oil without a prescription so long as that individual has a written certification from a Wisconsin-licensed physician that the oil is for therapy of a medical condition. The measure requires that certification be no more than one year old. It also stipulates that if the federal government changes its classification of CBD oil, the state will mirror those changes within thirty days.

Senator Van Wanggaard, R-Racine, who authored the legislation, said the measure permits families to use and possess CBD oil without fear of local or state prosecution He stated he was “ecstatic” to give hope to families across the state, adding the measure was the culmination of three years of work. “This bill is not only the compassionate thing to do, it is the right thing to do,” Wanggaard stated. “Parents shouldn’t have to risk jail time to treat their children. It is a sense of relief that we can ease the suffering and fear that too many parents experience trying to improve the lives of their children.”

While Democrats disputed the measure doesn’t solve complications in getting the oil, Wanggaard said it was a compromise and written narrowly to avoid issues related to cannabis laws. Officials emphasized the measure doesn’t legalize cannabis for medical or recreational purposes in Wisconsin. Wanggaard said people can travel to other states to obtain the oil and bring it back without being punished. State Senator Chris Larson voted yes but said more work needs to be done so families don’t have to travel out of state. Larson said during Senate debate, “We can move forward with this, but hold the confetti, pause the parade.” The Senate passed the measure 31-1, with Senator Duey Stroebel casting the only vote against it. It will soon go to the state Assembly. The full Assembly is likely to vote on it in March. Speaker Robin Vos has said passing the bill is a high priority.

Sally Schaeffer of Burlington, whose daughter is the law’s namesake, has been a leading supporter of CBD oil and legislation surrounding it. The original measure passed less than a month before Lydia Schaeffer died, having never received the therapy. Schaeffer said the bill was a good first step toward making the oil more readily available. She stated, “I’m thankful for Van’s efforts and those in the Senate listening to the people of Wisconsin.”

0 893

If legislators in Iowa don’t expand the current medical cannabis program, which basically allows residents to use CBD oil for the treatment of intractable epilepsy, there will be negative effects on MMJ patients. Without legislative action, the program expires on July 1 and Iowa’s 222 medical cannabis patients will be in jeopardized. The program already has its issues because it does not provide an avenue for Iowans to obtain CBD oil, or any medical cannabis products, in Iowa. Patients are required to travel to states where it is produced. Unfortunately, not all states permit the sale of medical marijuana products to people who aren’t residents.

That is why people like Cassie Helland are getting worried. Her 10-year-old son’s seizures stopped after two weeks of using CBD oil and never came back. Such cases like Caleb Helland’s epilepsy are not isolated. Ms. Helland and her fellow advocates have spent the past two years pressing legislators to expand the program. An editorial published in the Sioux City Journal said “lack of action returns the state, and those who suffer from epilepsy and other illnesses for which medical marijuana might help, to square one.” While the Iowa legislature took a crucial first step in 2014 and passed a limited medical marijuana program, the bill never addressed production and distribution of MMJ the state. In other words, Iowans with medical cannabis cards can possess CBD oil legally for epilepsy therapy, however, it is not legal to produce or distribute it. Cassie told the Quad-City Times that many families have to use their MMJ card to get CBD oil from states like Colorado.

Several states have medical cannabis reciprocity, including: Michigan, Pennsylvania, Nevada, Arizona, Maine, New Hampshire, and Rhode Island. Supporters for expansion say they would also like more forms of medical marijuana to be legalized for more conditions, such as PTSD and cancer. Sally Gaer of West Des Moines, co-founder of the advocacy group Iowans 4 Medical Cannabis, whose daughter has a rare form of epilepsy stated, “We are hopeful for a more comprehensive program that will help more Iowans. We have kids with epilepsy that need THCA (another compound that occurs naturally in the marijuana plant) because the oil doesn’t work for them, so they need a different component of the plant. So we need to help those kids.”

0 917

Cannabis biotech bellwether, GW Pharmaceuticals (GWPH) announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme (GBM).

Concurrent with this announcement, the company also reported first quarter financial results for the period that ended on December 31st. GW Pharma continues to be a leader within the cannabis biotech sector and today’s announcement further solidify its position at the top.

About the Study

GBM is a particularly aggressive brain tumor, with a poor prognosis. GW Pharma was granted the Orphan Drug Designation from the FDA and the EMA for THC:CBD in the treatment of glioma.

The study showed that patients with documented recurrent GBM treated with THC:CBD had an 83% one-year survival rate compared with 53% for patients taking the placebo. The median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group.

The treatment was generally well tolerated with the patients in both groups. The study reported that emergent adverse events caused two patients in each group to discontinue the study. The most common adverse events reported were vomiting and dizziness.

From the Principal Investigator and the CEO

Professor Susan Short, PhD, Professor of Clinical Oncology and Neuro-Oncology at Leeds Institute of Cancer and Pathology at St James’s University Hospital and principal investigator of the study said, “The findings from this well-designed controlled study suggest that the addition of a combination of THC and CBD to patients on dose-intensive temozolomide produced relevant improvements in survival compared with placebo and this is a good signal of potential efficacy. Moreover, the cannabinoid medicine was generally well tolerated. These promising results are of particular interest as the pharmacology of the THC:CBD product appears to be distinct from existing oncology medications and may offer a unique and possibly synergistic option for future glioma treatment.”

2017 Outlook is Bright

Following the company’s earnings report, GW Pharma CEO Justin Gover said, “As we look forward to 2017, our primary focus is on completing the Epidiolex NDA, which we expect to submit to the FDA in the middle of this year. With three positive Phase 3 trials delivered in 2016, we remain confident in the prospects for Epidiolex’s approval and are accelerating our preparations for a highly successful launch. Beyond Epidiolex, the value of GW’s cannabinoid platform is further illustrated by promising new clinical data in the field of oncology and we continue to advance a number of additional clinical programs that will yield data this year.”

Trades on FDA Results, Not Earnings

Although GW Pharma reported a $19.3 million net loss on $2.5 million in revenue during the quarter, we remain very favorable on the company as biotech stocks tend to trade on FDA results, not earnings.

As of December 31st, the company reported to have $444.6 million in cash and cash equivalents. This should provide the company enough capital to execute on 2017 corporate initiatives.

We are favorable on this update and continue to view GWPH as one of the top investment opportunities for cannabis investors due to its deep pipeline of products that are in advanced stages of FDA testing. The company’s pipeline should create catalysts for years to come and this is a stock every investor should watch.

0 2112

mCig, Inc. (MCIG) continued to show strong growth on a quarter-over-quarter basis after the company reported preliminary results for the third quarter which ended on January 31st.

mCig has shown incremental growth following the company’s transition from a pure-play vaporizer company to a diversified holding company focused on the legal cannabis, hemp, and CBD markets as well as the picks & shovels approach with Greenhouse & other cultivation construction projects via their Scalable Solutions division.

Highlights from the company’s third quarter include:

● Generated $1.3 million in revenue (200% higher than the prior quarter) through its construction, CBD, and e-Cig divisions
● Reported $845,000 in net income (adjusted net income of $118,00), a company record
● Generated $341,000 in cash from operations and increased its cash, and cash equivalents to $420,000
● Reported to have more than $1.2 million in current assets with only $287,000 in current liabilities. This provides mCig with an acid test ratio of 4.3:1, its highest rating in company history.

The company’s success in the third quarter has brought total revenue for this fiscal year to $2.2 million. The revenue generated represents a 546% increase from the same period last year, and a 204% increase from last quarter.

MCIG’s net income during the quarter increased its total net income for the fiscal year to $716,000 (32% net profit margin).

From the Management Team

Michael Hawkins, Chief Financial Officer, stated, “For the third straight quarter MCIG has recorded record numbers. With its current contracts and booked revenue the Company will continue to see quarter over quarter growth in revenue.” He went on to say, “During this quarter we will revamp our segment reporting; changing from construction, wholesale, and retail; to construction, CBD, and e-Cig operations. We feel reporting on the segments under these new categories will provide a greater in depth review of our operations to our shareholders and investors.”

mCig CEO Paul Rosenberg said, “The cannabis industry is growing rapidly and MCIG has been there since the beginning. Management continues to focus on its business grow opportunities in Nevada, while continuing to service other states as well.”

A Trend to Watch

Over the last year, mCig has expanded its offering as well as the states it operates out of. The company recently entered its first business agreement in Maine which marked the sixth state the company is operating out of.
Investors should keep an eye on MCIG as this is a company to watch as they continue to expand their cultivation construction arm in the Nevada market, which we anticipate will become the most lucrative market outside of California. The continued execution coupled with a more attractive product and service line has made mCig an attractive partner for many businesses and we expect to see further expansion from here.

We may buy or sell additional shares of (MCIG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER (http://marijuanastocks.com/content/terms-and-conditions-use/)

0 1345

Research from Western University concludes that a chemical found in cannabis can be helpful in schizophrenia therapy. Justine Renard, postdoctoral fellow in Western’s Department of Anatomy and Cell Biology at the Schulich School of Medicine and Dentistry who led the study, identifies the neural pathway whereby the marijuana-derived phytochemical cannabidiol (CBD) produces antipsychotic effects that are discovered to ease symptoms of schizophrenia-related psychosis. The study’s authors stated, “These findings have critical implications not only for understanding how specific phytochemical components of marijuana may differentially impact neuropsychiatric phenomena, but demonstrate a potential mechanism for the therapeutic effects of marijuana derivatives in the treatment of dopamine-related, psychiatric disorders.”

Cannabis contains two main chemicals responsible for producing its psychoactive properties: the more well-known tetrahydrocannabinol (THC) and CBD. While THC serves to produce the drug’s psychoactive properties, CBD has been discovered to have an opposing, antipsychotic effect that makes it potentially ideal for use in treatment of psychoses such as schizophrenia. The link between marijuana and schizophrenia has been known for some time, as studies have shown that heavy cannabis use increases the risk of developing schizophrenia and that schizophrenics who use marijuana are more liable to have worsening symptoms and further progression of the illness. However, recent evidence including the work done at the Western University lab points to THC as the culprit rather than CBD.

Co-author Steven Laviolette stated, “CBD is acting in a way that is the exact opposite to what THC is doing. Within the same plant, you’ve got two different chemicals that are producing opposite effects in terms of psychiatric effects, molecular signaling and effects on the dopamine pathway.” Researchers injected rats with CBD to study its behavioural, chemical, and neuropathic effects and discovered that it serves to cut back dopamine sensitization, a response that has been linked to schizophrenia-related psychoses. This helps to explain exactly how CBD affects brain functioning. Laviolette stated, “One of the biggest problems in treating schizophrenia is that there hasn’t been an effective new treatment on the market in a very long time. The drugs on the market today have limited efficacy and horrible side-effects. There is a desperate need for safer alternative medications.”

0 2693

Reports of hemp-based CBD medicine’s death have been highly exaggerated. That’s the word from several legal experts who say, despite a moment of industry-wide panic about the DEA’s filing of a memo with the federal register establishing a “final rule” on the internal classification of “marijuana extracts” the law regarding CBD and hemp has not changed. A memo from Folium Legal Counsel reflects this widespread interpretation of the law and the lack of negative impacts on the industry since the filing took effect.

From the Folium memo:
Previously, Marijuana Extracts were classified under the code number for “Marijuana. Under the new rule, extracts are now classified separately. The DEA uses these codes to track quantities of controlled substances imported to and exported from the United States. This new rule affects only DEA-registered entities who previously were required to track such materials. As the document states, “The only direct effect to registrants who handle marijuana extracts will be the requirement to add the new drug code to their registrations.”

The DEA has claimed that the reclassification was meant to comply with international drug control treaties, and to better monitor the ways in which scientists are studying extracts versus cannabis flowers. Their plan is to institute new code numbers for marijuana extracts, which the DEA defines as “an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.’’

Joshua Kappel is a partner at Vicente & Sederberg, which Rolling Stone called “the country’s first powerhouse marijuana law firm.” He said the DEA’s explanation is reasonable and comports with the nature of the agency’s filing. Kappel stated, “I do believe the DEA when they say this an administrative move towards clarity. There is no drug that is illegal now that was legal before. The DEA has to work with Congress to reschedule a substance, the ruling [Hemp Industries Assoc. LLC v. DEA] still stands.” The Rohrabacher-Farr amendment, which became law in 2014, prevents the Justice Department from interfering with state laws and regulations on medical cannabis. The amendment further covers the 16 states that allow CBD use only. Additionally, industrial hemp and its derivatives are currently legal in all 50 states.

From the Folium memo:
Regarding the legal status of CBD derived from industrial hemp: The 2014 US Farm Bill was an act of congress signed by the president and that is the highest law of the land. The DEA cannot make law and try to redefine a law passed by the US Congress which defined industrial hemp in section 7606 as “Any cannabis sativa L that produces naturally less than .3% THC on a dry weight basis.”

0 1600

A notice published last month in the Federal Register by the United States Drug Enforcement Administration (DEA) has formed varied reactions in the growing CBD (cannabidiol) industry and may soon result in a court battle over the legality of a substance that federal law enforcement considers a marijuana extract. The DEA reported a final rule to create a new Administration Controlled Substances Code Number for marijuana extract in December, clarifying in response to a comment submitted to the agency that CBD would fall within the new drug code. Marijuana extracts will remain a Schedule 1 controlled substance. The DEA explained the new drug policy would enable the agency to track quantities of cannabis extract separately.

The DEA said in the notice, “The creation of a new drug code in the DEA regulations for ‘marijuana’ extracts will allow for more appropriate accounting of such materials consistent with treaty provisions.” Hemp lawyers have disputed the DEA’s rule is inconsistent to the 2014 Farm Bill signed by Former President Barack Obama. Section 7606 of the 2014 Farm Bill authorized the growth and farming of industrial hemp, from which CBD seemingly derives. However, the notice raised worry that the DEA would move to crack down on producers and marketers of CBD, which has been researched as a medicine to treat epilepsy and widely marketed in dietary supplements.

Worried that CBD would be treated as a Schedule 1 narcotic, Jonathan Miller, a lawyer in Lexington, KY, with the firm Frost Brown Todd LLC, described as “apocalyptic” some initial reactions in the industry to DEA’s notice. “DEA cannot rewrite federal law, and federal law is very clear, particularly. Hemp that is grown pursuant to a pilot program, that the Controlled Substances Act is exempted,” Miller said in a phone interview. “We do not feel the DEA rule changes anything, especially for people who are part of hemp pilot programs,” Miller stated.

Yet, some hemp leaders are getting ready for a possible legal battle with the DEA in response to its notice. The new drug code is expected to take effect soon. The Hemp Industries Association stated last month in a press release, “The DEA final rule is concerning to the industry, as it creates confusion in the marketplace among consumers and legitimate businesses alike, and may potentially result in federal agencies improperly treating legal products such as CBD oils, body balms, and supplements as controlled substances.” The trade group added it was “strongly considering legal action” to protect the hemp industry.

0 11440

How Have Marijuana Stocks Performed Post Trump?

Here we are, the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.

As we’ve said in the past, a lot of marijuana stocks are event driven. Going all the way back to 2014 and during the years to follow, catalysts in the cannabis market can be tied to actual events in many cases. For this most recent jump in marijuana stock prices, we see that an election year and a not so conservative President may be the event to thank for this.

In this article we’ll briefly explore some of the most active and most bullish marijuana stocks in the market to give a clear example of “where we’ve been” and what we might be able to look forward to as to “where we’re going”.

OWC Pharmaceutical Research Corp. (OWCP) 3,512%

This company has been building steam since October and just recently went into overdrive to all time highs. Through its subsidiary, One World Cannabis, the Israeli-based company develops cannabinoid-based therapies that target different medical conditions. This was another cannabis biotech company that saw the impact of Trump coming into office instead of Clinton (who was very bearish on biotech).

In late October just before the elections, OWCP saw its first noticeable move from under $0.03 and initially ran to highs of $0.215. Following the consolidation period heading into the end of the year (as most marijuana stocks saw), January opened the door for this stock to run as high as $0.95



Rocky Mountain High Brands (RMHB)

We’ve reported on this company and followed it for a few years. Even before when it was “Totally Hemp Crazy (THCZ)” this stock saw one of the biggest breakouts that we’ve every witnessed. It went from sub penny to highs of 0.32 within weeks. Now it appears that chart has demonstrated a similar Trump Bump that many of the other marijuana stocks have also seen.

In early October, volume began to build, RMHB ran from $0.031 to highs of $0.07. After consolidating back to 0.03-0.04, RMHB has now seen its 2017 rally trigger and has now managed to run past $0.11. Rocky Mountain is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low-calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots, as well as a Relaxation Brownie.

Marijuana Stock

Ubiquitech Software Corp. (UBQU)

UBQU follows a similar trend where even though it hasn’t broken above its year end highs, the stock has seen a reversal that started at the beginning of 2017. A lot of questions were raised regarding a previously announced name change and recently the company gave clear guidance on this for 2017 that has brought attention back to the stock from market bulls. Its final name change will be Endo BioSciences Inc., and HempLife Today™ will continue to be the main subsidiary of the company.

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; its popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid.

marijuana stocks

mCig, Inc. (MCIG)

A company that we’ve kept up with for the better part of the last year, MCIG became another clear example of what marijuana stocks have started to look like after Donald Trump was elected President. The company has been making many key strides over the last few months including posting some of its best numbers in history.

This includes MCIG currently holding over $10 million in order/contract backlog (as of their last PR in December). In similar fashion to OWCP, shares of MCIG saw a bump in late October when the stock moved from under $0.04 to as high as $0.218. After consolidating in early December, MCIG manage to rally strong heading into the end of the year and recently hit highs of $0.505.

cannabis stocks

Axim Biotechnologies, Inc. (AXIM)

Another company that we’ve been following very closely, this has been one of the biggest runners of the year amid heavy volatility. Another cannabis biotech, the company focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. MJNA is also an investor in AXIM.

In late October the stock was trading just under $0.50 moved to a high of $10 before consolidating to levels between $7.50-$8. Wouldn’t you know it, heading into the beginning of 2017 the stock broke the sideways trend and moved to highs of $19.80.

cannabis stock

Vitality Biopharma (VBIO)

A company that many of us are familiar with, this cannabis biotech had a smaller run a few weeks before we started picking up coverage. In early October, the stock moved up from around $0.92 to highs of $1.84. After pulling back to lows in December, we began looking at this company at $0.98 and watched as it ran to highs of $4.24. The company is a cannabis biotech focusing on treating disease through its prodrug utilizing cannabinoids for the treatment of serious neurological and inflammatory disorders.


Cannabis Science (CBIS)

The company specializes in the development of cannabinoid-based medications and recently announced a collaborative research agreement with Dana Farber/Harvard Cancer Center. Their initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

From October 3 to October 19 CBIS jumped from $0.0169 to as high as $0.077. After pulling in during December, the stock kicked off the new year with a big bull run all the way to highs of $0.0961 for the year so far.


Hemp Inc. (HEMP)

One of the most vocal companies on Hemp production in the US, Hemp Inc. They’ve continued to push for a ubiquitous acceptance for all uses of the hemp plant for years now and have targeted North Carolina to grow over 3,000 acres of hemp.

“We are proud to collaborate with other American industrial hemp farmers as we now become part of the modern industrial hemp farming movement. This is a turning point for America and it’s a turning point for Hemp, Inc. Hemp, Inc. has the infrastructure in place to process millions of pounds of hemp fibers and stalks a year, on a commercial level. Our 70,000 square foot industrial hemp processing facility, on over 9 acres in Spring Hope, North Carolina, is the only one of this magnitude in North America. The industrial hemp crop is part of history in the making and it is something that will prove to be lucrative not only for the farmers in North Carolina but for Hemp, Inc. as well,” said CEO Bruce Perlowin in a recent PR.

HEMP saw a bump in volume early in October, the stock ran from $0.0276 to $0.056 before consolidating in late November/December, and has once again begun to aggressively climb back from that price channel.


Cannabis Sativa, Inc. (CBDS)

With multiple subsidiaries, this company has products ranging from hemp oils & capsules to cannabidiol infused bottled water and even its own patented cannabis plan named Ecuadorian Sativa (Patent PP27,475). Back in late September the stock was trading around $2.80 per share before it jumped up to highs of $8.25. After consolidating for weeks leading up to the new year, CBDS has once again followed suit of many marijuana stocks having now climbed back above $8.



This leads us to our “neighbors up north” because we haven’t just seen a boom from US marijuana stocks alone. The trend has echoed into Canada with some of the most anticipated IPOs so far this year


Emblem Corp, a Licensed Cultivator out of Paris Ontario is one of the most watched and anticipated offerings that has come out of Canada in the last few months. Beyond the fact that they are already growing cannabis and revenue producing investors have taken note of one of their founders and current President, a gentleman by the name of John Stewart.

No, not John Stewart from the Daily Show even though that would be awesome, John Stewart former CEO of Purdue Pharma one of the largest private biotech companies in the world and creators of OxyContin. We see the potential long term to create a cultivator/Biotech hybrid in which case Emblem could be the Next GW Pharma of Canada.

Marijuana IPO

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CNSX: IN)

This company has been following the same pattern as many of the other cannabis biotechs but also comes with what looks to be a stock promotion behind it. The company recently appointed Jeff Charpentier, CPA, CA as InMed’s Chief Financial Officer & Corporate Secretary as well as Martin Bott to its Board of Directors; Bott has worked at Eli Lilly & Company since 1988 and held a variety of roles in the U.S., Switzerland, Germany, and the UK.

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. IMLFF saw a rise in price early in October (shocker right?), a period of consolidation leading up to the new year, and since that ball dropped, the stock has been on the run moving from $0.10 in October to highs of $0.4261 just a few days ago.

Marijuana Stocks

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF)

The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada.

They just announced that the company has officially surpassed 12,000 registered patients within the first 12 months of product sales in Canada. They also announced that they had signed a Joint Venture Research Agreement with Radient Technologies Inc. (“RTI”). The first phase of this venture will include screening experiments of extraction conditions, while phase two includes larger scale experiments related to extraction throughput and optimal extraction conditions. Aurora’s scientists and the RTI team will commence tests January 16, 2017, and the first phase is expected to be completed within approximately six weeks, so something to keep an eye on here in our opinion.

Likewise with the other stocks, the market activity has followed suit even though Aurora has differed by not breaking a new high this year as compared to the high it made in November. But the new uptrend on the chart could be a key indicator for future potential. Since October (at $1.06), shares of ACBFF has seen two and possibly three clear runs; One that saw highs of $1.89 before consolidating, another that saw highs of $2.96 before consolidating, and possibly a new uptrend forming now in January.

Buy marijuana stocks

These are just a few marijuana stocks that have demonstrated a near identical move in the market both leading into the election and leading up to the inauguration. We’ve said it before and most likely will say it again: Marijuana Stocks can very much be event driven so something to keep in the back of your head as we watch 2017 unfold. As investors become more informed on the industry itself, we’ll keep our had on the pulse to find the real story behind some of the biggest marijuana stock moves in the market today.







Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. MAPH owns 2 million common restricted shares of mCig Inc. MAPH owns 10 million common restricted shares of Hemp Inc. An affiliate of MAPH owns 70,850 common restricted shares of Emblem Corp. We may buy or sell additional shares of any stocks mentioned, in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information

1 1318

Lexaria and NeutriSci Announce Successful Cannabinoid Tablet Development and Positive Results from Initial Human Observational Trials

Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”) and NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU, Frankfurt-1N9) are pleased to announce the successful development and initial trial of the industry’s first zero-sugar cannabinoid / pterostilbene edible tablet utilizing both Neutrisci’s and Lexaria’s proprietary and patented technologies.

Neutrisci’s proprietary pterostilbene tablet formula was used to produce the world’s first pterostilbene / cannabidiol (CBD) rapid melt edible product offering the benefits of Lexaria’s patented CBD conjugation technology. The market-ready tablet offers improvements in taste, rapidity of onset, and strength of effect due to greater bioavailability, as had been originally hypothesized.

After trial batch formulation and manufacturing was completed, observational human tests supported that the user will experience the effects faster and last longer while utilizing smaller amounts of cannabinoid than competing products. The above noted benefits offer manufacturing efficiencies over competing products, thus potentially increasing comparative profitability.

NeutriSci and Lexaria confirm the companies expect to officially bind the JV agreement to market and commercialize a line of edible products using CBD derived from full spectrum hemp oil, which is federally legal in the United States, to be followed by tetrahydrocannabinol (THC) versions through distribution programs with both existing and planned new strategic partners. With successful first-stage formulation and human evaluation completed, the companies expect to conclude a working JV structure as soon as possible to financially capitalize on this unique opportunity.

“This joint venture is a demonstration of the rapid innovation occurring in the cannabis industry,” commented Chris Bunka, CEO of Lexaria Bioscience. “We are excited to work with NeutriSci; to combine both technology and form factor to develop healthy cannabinoid products to be sold within NeutriSci’s international distribution network.”

“We are very pleased with the results of this product formulation and observational trial, as the initial results have be invaluable in helping NeutriSci open dialogue with several of the world’s largest CBD manufactures and distributors,” commented Glen Rehman, President of NeutriSci International. “The idea to use our sublingual tablet and form factor to create a new line of zero-sugar and dose-controlled cannabinoid edible products will become a reality.”

Following the recent approvals for recreational use in certain US states, industry researchers have reported that the legal cannabis market could exceed $20 Billion by 2020.

About Lexaria

Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.


About NeutriSci International Inc.

NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci has focused on the development of several breakthrough nutraceutical products with an initial focus on areas such as heart and cholesterol health, sleep deprivation therapies, immune defense, as well as men’s prostate and sexual health. NeutriSci continues to build strong relationships and distribution channels for its BluScience™ and NeuEnergy™ products with retailers throughout the United States. NeutriSci is focusing efforts in strengthening sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers.


Lexaria Bioscience Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements